April 12, 2022
Engitix Announces Expanded Collaboration and Licensing Agreement with Takeda to Develop New Anti-Fibrotic Therapies in Inflammatory Bowel Disease
Engitix Ltd (‘Engitix’), a biotechnology company developing a portfolio of programmes in fibrosis and solid tumours using its proprietary human extracellular matrix (ECM) platform, has entered into an agreement with Takeda to expand an existing collaboration to now include the discovery and development of novel therapeutics for fibrostenotic inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis.